Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College, No.167 Beilishi Road, Xicheng district, Beijing, China.
Department of Blood Transfusion, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College, No.167 Beilishi Road, Xicheng district, Beijing, China.
BMC Anesthesiol. 2019 Jul 15;19(1):129. doi: 10.1186/s12871-019-0772-0.
The efficacy of tranexamic acid (TXA) to reduce perioperative blood loss and allogeneic blood transfusion in cardiac surgeries has been proved in previous studies, but its adverse effects especially seizure has always been a problem of concern. This meta-analysis aims to provide information on the optimal dosage and delivery method which is effective with the least adverse outcomes.
We searched Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE for all relevant articles published before 2018/12/31. Inclusion criteria were adult patients undergoing elective heart surgeries, and only randomized control trials comparing TXA with placebo were considered. Two authors independently assessed trial quality and extracted relevant data.
We included 49 studies with 10,591 patients into analysis. TXA significantly reduced transfusion rate (RR 0.71, 95% CI 0.65 to 0.78, P<0.00001). The overall transfusion rate was 35%(1573/4477) for patients using TXA and 49%(2190/4408) for patients in the control group. Peri-operative blood loss (MD - 246.98 ml, 95% CI - 287.89 to - 206.06 ml, P<0.00001) and re-operation rate (RR 0.62, 95% CI 0.49 to 0.79, P<0.0001) were also reduced significantly. TXA usage did not increase risk of mortality, myocardial infarction, stroke, pulmonary embolism and renal dysfunction, but was associated with a significantly increase in seizure attack (RR 3.21, 95% CI 1.04 to 9.90, P = 0.04).The overall rate of seizure attack was 0.62%(21/3378) for patients using TXA and 0.15%(5/3406) for patients in the control group. In subgroup analysis, TXA was effective for both on-pump and off-pump surgeries. Topical application didn't reduce the need for transfusion requirement, while intravenous delivery no matter as bolus injection alone or bolus plus continuous infusion were effective. Intravenous high-dose TXA didn't further decrease transfusion rate compared with low-dose regimen, and increased the risk of seizure by 4.83 times. No patients in the low-dose group had seizure attack.
TXA was effective in reducing transfusion requirement in all kinds of cardiac surgeries. Low-dose intravenous infusion was the most preferable delivery method which was as effective as high-dose regimen in reducing transfusion rate without increasing the risk of seizure.
已有研究证明,氨甲环酸(TXA)可减少心脏手术围手术期的失血和异体输血,但其不良反应,尤其是癫痫发作,一直是令人关注的问题。本荟萃分析旨在提供有关最佳剂量和给药方法的信息,这些方法在产生最少不良反应的情况下是有效的。
我们检索了 Cochrane 对照试验中心注册库、MEDLINE 和 EMBASE,以获取截至 2018 年 12 月 31 日之前发表的所有相关文章。纳入标准为择期心脏手术的成年患者,且仅纳入比较 TXA 与安慰剂的随机对照试验。两位作者独立评估试验质量并提取相关数据。
我们纳入了 49 项研究共 10591 例患者进行分析。TXA 显著降低了输血率(RR 0.71,95%CI 0.65 至 0.78,P<0.00001)。使用 TXA 的患者总体输血率为 35%(1573/4477),而对照组为 49%(2190/4408)。围手术期出血量(MD -246.98ml,95%CI -287.89 至 -206.06ml,P<0.00001)和再次手术率(RR 0.62,95%CI 0.49 至 0.79,P<0.0001)也显著降低。TXA 的使用并未增加死亡率、心肌梗死、中风、肺栓塞和肾功能不全的风险,但与癫痫发作的风险显著增加相关(RR 3.21,95%CI 1.04 至 9.90,P=0.04)。使用 TXA 的患者癫痫发作的总体发生率为 0.62%(21/3378),而对照组为 0.15%(5/3406)。在亚组分析中,TXA 对体外循环和非体外循环手术均有效。局部应用并不能降低输血需求,而静脉给药无论是单独推注还是推注加持续输注均有效。静脉高剂量 TXA 并没有进一步降低输血率,反而使癫痫发作的风险增加 4.83 倍。低剂量组没有患者出现癫痫发作。
TXA 可有效减少各种心脏手术的输血需求。静脉低剂量输注是最可取的给药方法,与高剂量方案一样,可降低输血率,而不增加癫痫发作的风险。